Suchergebnisse - "Yamada, Tadaaki"

PubPharm (282)

1

Comparing Three Different Anti-Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC : A Prospective Study

enthalten in: JTO clinical and research reports | 2024

von Katayama, Y. | Yamada, T. | Morimoto, K. | +17

2

POLD1 Is Required for Cell Cycle Progression by Overcoming DNA Damage in Malignant Pleural Mesothelioma

enthalten in: Cancer genomics & proteomics | 2024

von Shimizu, D. | Ishibashi, M. | Yamada, T. | +3

3

Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer : Focus on Older Patients

enthalten in: Targeted oncology | 2024

von Onoi, K. | Yamada, T. | Morimoto, K. | +14

4

AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells

enthalten in: Cancer letters | 2024

von Morimoto, K. | Yamada, T. | Hirai, S. | +22

5

Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer

enthalten in: Cancer science | 2024

von Ishida, M. | Iwasaku, M. | Doi, T. | +11

6

Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells

enthalten in: Molecular cancer therapeutics | 2024

von Hirai, S. | Yamada, T. | Katayama, Y. | +10

7

Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer

enthalten in: The oncologist | 2024

von Katayama, Y. | Yamada, T. | Sawada, R. | +13

8

Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50

enthalten in: Frontiers in immunology | 2024

von Takei, S. | Kawachi, H. | Yamada, T. | +20

9

Impact of the response to platinum-based chemotherapy on the second-line immune checkpoint inhibitor monotherapy in non-small cell lung cancer with PD-L1 expression ≤49% : a multicenter retrospective study

enthalten in: Frontiers in oncology | 2024

von Yoshimura, A. | Takeda, T. | Kataoka, N. | +18

10

A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy : The SPIRAL-RT study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Yamada, T. | Goto, Y. | Tanaka, H. | +9

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[29]